Pharmaceutical Raw Materials

Safotibant (INN) also known by the research code LF22-0542 is a non-peptide bradykinin B1 antagonist. It displayed binding Ki values of 0.35 and 6.5 nM at cloned human and mouse B1 receptors, respectively, while having no affinity for either human, mouse, or rat B2 receptors at concentrations up to 10 μM. This means that LF22-0542 is at least 4000 times selective for the B1 receptor over the B2 receptor. Systemic administration of LF22-0542 inhibited acute pain induced by acetic acid, formalin, and a hot plate. It also reversed acute inflammatory pain induced by carrageenan, and persistent inflammatory pain induced by CFA. In a neuropathic pain model, LF22-0542 reversed the thermal hyperalgesia, but not the mechanical hyperalgesia.

Fluorodeoxyglucose is a fluoro derivative of 2-deoxyglucose. Its complete chemical name is 2-fluoro-2-deoxy-D-glucose, usually referred to as 18F-FDG or FDG. FDG is most commonly used in medical imaging equipment of positron emission tomography (PET): Fluorine in FDG molecules is fluorine-18 (fluorine-18, F-18, 18F, 18 fluorine), which belongs to positron emission radioisotope, so it becomes 18F-FDG (fluorine - [18F] deoxyglucose). After injecting FDG into the patient (patient, patient), the PET scanner can construct an image reflecting the distribution of FDG in the body. Then, the nuclear medicine physician or radiologist evaluates these images to make a diagnosis of various medical health conditions.

This product is a kind of semi synthetic oxime cephalosporin, which is a pharmaceutical raw material and used as an antibacterial drug.

Clopamide is a thiazide diuretic with oral activity, which can inhibit the sodium coupled chloride cotransporter SLC12A3. Clopamide can be used in the study of hypertension and heart failure.

Indobufen is an anti platelet aggregation drug. It can selectively act on circulating platelets, block thrombosis, inhibit the release of platelet factors and play an anti platelet aggregation role. This inhibition is reversible, does not change plasma parameters, does not damage platelet function, and returns abnormal platelet function to normal. It can significantly improve the microcirculation parameters and walking distance of patients with peripheral vascular disease and intermittent claudication. It has the same effect as aspirin and dipyridamole in preventing obstruction after coronary artery shunt and femoral artery shunt; During hemodialysis, it can significantly reduce platelet deposits on the dialysis membrane. This product can also prevent secondary thrombosis after transient ischemic attack or mild stroke. Compared with similar drugs, indobufen inhibits platelet factor, and its anti platelet aggregation effect is 2 ~ 5 times that of salicylic acid, with slightly shorter bleeding time. Compared with ticlopidine, there was no significant difference in oral clinical efficacy, but indobufen showed good tolerance.